Enhancing anti-cancer virotherapy with heat-shock protein-mediated immune response.
Guo
Wei
W
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Fang
Bingliang
B
D000256:Adenoviridae / Q000235:genetics; D017500:Adenovirus E1A Proteins / Q000235:genetics; D000818:Animals; D005822:Genetic Vectors / Q000008:administration & dosage* / Q000235:genetics; D018840:HSP70 Heat-Shock Proteins / Q000378:metabolism; D006360:Heat-Shock Proteins / Q000378:metabolism*; D007371:Interferon-gamma / Q000032:analysis / Q000276:immunology; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental; D050130:Oncolytic Virotherapy / Q000379:methods*; D016019:Survival Analysis; D023041:Xenograft Model Antitumor Assays / Q000379:methods
D017500:Adenovirus E1A Proteins; D018840:HSP70 Heat-Shock Proteins; D006360:Heat-Shock Proteins; D007371:Interferon-gamma